Michael W. Deininger

48.7k total citations · 12 hit papers
399 papers, 21.2k citations indexed

About

Michael W. Deininger is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Michael W. Deininger has authored 399 papers receiving a total of 21.2k indexed citations (citations by other indexed papers that have themselves been cited), including 355 papers in Hematology, 304 papers in Genetics and 140 papers in Rheumatology. Recurrent topics in Michael W. Deininger's work include Chronic Myeloid Leukemia Treatments (324 papers), Chronic Lymphocytic Leukemia Research (254 papers) and Eosinophilic Disorders and Syndromes (139 papers). Michael W. Deininger is often cited by papers focused on Chronic Myeloid Leukemia Treatments (324 papers), Chronic Lymphocytic Leukemia Research (254 papers) and Eosinophilic Disorders and Syndromes (139 papers). Michael W. Deininger collaborates with scholars based in United States, Germany and United Kingdom. Michael W. Deininger's co-authors include Brian Druker, John M. Goldman, Junia V. Melo, Thomas O’Hare, Christopher A. Eide, Elisabeth Buchdunger, Amie S. Corbin, Jörge E. Cortes, Andreas Hochhaus and Marc Loriaux and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Michael W. Deininger

384 papers receiving 20.7k citations

Hit Papers

The molecular biology of chronic myeloid leukemia 2000 2026 2008 2017 2000 2004 2009 2005 2017 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The molecular biology of chronic myeloid leukemia
    2000 1.2k citations Michael W. Deininger, Junia V. Melo et al. Blood profile →
  2. The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    2004 960 citations Michael W. Deininger, Brian Druker et al. Blood profile →
  3. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
    2009 890 citations Jörge E. Cortes, Jane F. Apperley et al. Journal of Clinical Oncology profile →
  4. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
    2005 812 citations Thomas O’Hare, Denise K. Walters et al. Cancer Research profile →
  5. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    2017 797 citations Andreas Hochhaus, Jerald P. Radich et al. profile →
  6. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
    2000 616 citations Michael W. Deininger, Junia V. Melo et al. Blood profile →
  7. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    2010 586 citations Amie S. Corbin, Anupriya Agarwal et al. profile →
  8. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
    2012 527 citations Jörge E. Cortes, Hagop M. Kantarjian et al. profile →
  9. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
    2009 444 citations Michael W. Deininger, Andreas Hochhaus et al. Blood profile →
  10. OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
    2013 356 citations Jason Gotlib, Anupriya Agarwal et al. profile →
  11. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    2017 320 citations Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology profile →
  12. Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
    2015 319 citations Michael W. Deininger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael W. Deininger United States 67 16.3k 12.5k 7.5k 4.9k 3.2k 399 21.2k
Giuseppe Saglio Italy 75 18.5k 1.1× 13.4k 1.1× 7.0k 0.9× 5.6k 1.2× 4.3k 1.3× 650 25.0k
Carlo Gambacorti‐Passerini Italy 56 7.9k 0.5× 5.5k 0.4× 3.3k 0.4× 5.0k 1.0× 2.9k 0.9× 342 13.7k
Elias Jabbour United States 80 18.1k 1.1× 9.4k 0.8× 3.9k 0.5× 6.9k 1.4× 6.1k 1.9× 1.2k 25.4k
Elisabeth Buchdunger Switzerland 42 8.7k 0.5× 5.6k 0.4× 3.9k 0.5× 5.7k 1.2× 4.4k 1.4× 60 17.4k
Oliver G. Ottmann Germany 62 10.4k 0.6× 5.0k 0.4× 2.8k 0.4× 4.9k 1.0× 4.0k 1.2× 372 16.1k
Nicholas Lydon Switzerland 29 7.2k 0.4× 4.8k 0.4× 3.3k 0.4× 3.9k 0.8× 2.7k 0.8× 40 12.6k
Renaud Capdeville Switzerland 29 6.8k 0.4× 5.0k 0.4× 3.3k 0.4× 3.0k 0.6× 2.8k 0.9× 52 13.0k
Deborah A. Thomas United States 80 12.3k 0.8× 10.2k 0.8× 2.6k 0.3× 6.3k 1.3× 4.9k 1.5× 451 23.2k
Junia V. Melo United Kingdom 49 7.3k 0.4× 5.6k 0.4× 3.2k 0.4× 2.7k 0.6× 1.8k 0.6× 119 10.2k
Paul W. Manley Switzerland 50 5.9k 0.4× 4.2k 0.3× 2.7k 0.4× 3.4k 0.7× 2.0k 0.6× 153 10.6k

Countries citing papers authored by Michael W. Deininger

Since Specialization
Citations

This map shows the geographic impact of Michael W. Deininger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Deininger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Deininger more than expected).

Fields of papers citing papers by Michael W. Deininger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Deininger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Deininger. The network helps show where Michael W. Deininger may publish in the future.

Co-authorship network of co-authors of Michael W. Deininger

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Deininger. A scholar is included among the top collaborators of Michael W. Deininger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Deininger. Michael W. Deininger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.
2.
高橋, 義行, Xiaomeng Huang, Philip J. Moos, et al.. (2024). A Bayesian framework to study tumor subclone–specific expression by combining bulk DNA and single-cell RNA sequencing data. Genome Research. 34(1). 94–105. 2 indexed citations
3.
Constance, Jonathan E., Mary McFarland, Michael W. Deininger, et al.. (2023). Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. JMIR Research Protocols. 12. e38167–e38167. 1 indexed citations
4.
Zhao, Helong & Michael W. Deininger. (2023). ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS. Blood. 141(23). 2797–2812. 9 indexed citations
5.
Cross, Nicholas C.P., Thomas Ernst, Susan Branford, et al.. (2023). European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 37(11). 2150–2167. 37 indexed citations
6.
Garrett, May, et al.. (2023). Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Medicine. 12(17). 17981–17992. 5 indexed citations
7.
Brümmendorf, Tim H., Jörge E. Cortes, Dragana Milojković, et al.. (2022). Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 36(7). 1825–1833. 79 indexed citations
8.
Shah, Fenil, Justyna M. Gawel, Yasir S. Raouf, et al.. (2019). Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. Journal of Medicinal Chemistry. 62(5). 2651–2665. 28 indexed citations
9.
Eiring, Anna M., Jonathan M. Ahmann, Clinton C. Mason, et al.. (2017). Loss of G0S2 in Kinase-Independent TKI Resistance and Blastic Transformation of CML. Blood. 130. 4173–4173. 1 indexed citations
10.
Pomicter, Anthony D., Clinton C. Mason, Anna M. Eiring, et al.. (2017). Inhibition of Nucleocytoplasmic Export Enhances Selective Elimination of Leukemic Stem Cells in Chronic Myeloid Leukemia. Blood. 130. 42–42.
11.
O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations
12.
Corbin, Amie S., Thomas O’Hare, Zhimin Gu, et al.. (2013). KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. Cancer Research. 73(18). 5775–5786. 17 indexed citations
13.
Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations
14.
O’Hare, Thomas, Matthew S. Zabriskie, Anna M. Eiring, & Michael W. Deininger. (2012). Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature reviews. Cancer. 12(8). 513–526. 227 indexed citations
15.
Eide, Christopher A., Lauren T. Adrian, Jeffrey Tyner, et al.. (2011). The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Research. 71(9). 3189–3195. 77 indexed citations
16.
Rosée, Paul La, Taiping Jia, Nicolai Härtel, et al.. (2006). Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib. Clinical Cancer Research. 12(21). 6540–6546. 23 indexed citations
17.
Bumm, Thomas G.P., Collin Elsea, Amie S. Corbin, et al.. (2006). Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease. Cancer Research. 66(23). 11156–11165. 151 indexed citations
18.
Demehri, Shadmehr, Amie S. Corbin, Marc Loriaux, Brian Druker, & Michael W. Deininger. (2006). Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Experimental Hematology. 34(3). 284–288. 19 indexed citations
19.
O’Hare, Thomas, Denise K. Walters, Eric P. Stoffregen, et al.. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 65(11). 4500–4505. 812 indexed citations breakdown →
20.
Dinulescu, Daniela M., Lisa J. Wood, Lei Shen, et al.. (2003). c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 22(55). 8852–8860. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Saglio Breakdown of academic impact, for papers by Carlo Gambacorti‐Passerini Breakdown of academic impact, for papers by Elias Jabbour Breakdown of academic impact, for papers by Elisabeth Buchdunger Breakdown of academic impact, for papers by Oliver G. Ottmann Breakdown of academic impact, for papers by Nicholas Lydon Breakdown of academic impact, for papers by Renaud Capdeville Breakdown of academic impact, for papers by Deborah A. Thomas Breakdown of academic impact, for papers by Junia V. Melo Breakdown of academic impact, for papers by Paul W. Manley
Rankless by CCL
2026